{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:28:46Z","timestamp":1793039326382,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Reg Anesth Pain Med"],"accepted":{"date-parts":[[2025,5,22]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gabapentin is widely used to treat chronic pain, but its association with cognitive decline and dementia remains unclear. This study examined whether gabapentin prescription is associated with dementia in adults with chronic low back pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the TriNetX national database of de-identified patient records from 2004 to 2024. Adults diagnosed with chronic low back pain were included; those with prior gabapentin use, dementia, epilepsy, stroke, or cancer were excluded. Propensity score matching controlled for demographics, comorbidities, and pain medications. Patients were stratified by age and gabapentin prescription frequency. Primary outcomes were dementia and mild cognitive impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>26,416 adults we analyzed following propensity-score matching. Patients with six or more gabapentin prescriptions had an increased incidence of dementia (RR: 1.29; 95% CI: 1.18\u20131.40) and mild cognitive impairment (RR: 1.85; 95% CI: 1.63\u20132.10). When stratified by age, non-elderly adults (18\u201364) prescribed gabapentin had over twice the risk of dementia (RR: 2.10; 95% CI: 1.75\u20132.51) and mild cognitive impairment (RR: 2.50; 95% CI: 2.04\u20133.05) compared to those not prescribed gabapentin. Risk increased further with prescription frequency: patients with 12 or more prescriptions had a higher incidence of dementia (RR: 1.40; 95% CI: 1.25\u20131.57) and mild cognitive impairment (RR: 1.65; 95% CI: 1.42\u20131.91) than those prescribed gabapentin 3\u201311 times.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Gabapentin prescription in adults with chronic low back pain is associated with increased risk of dementia and cognitive impairment, particularly in non-elderly adults. Physicians should monitor cognitive outcomes in patients prescribed gabapentin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rapm-2025-106577","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:13Z","timestamp":1752192013000},"page":"1118-1123","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Risk of dementia following gabapentin prescription in chronic low back pain patients"],"prefix":"10.1136","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8595-3342","authenticated-orcid":false,"given":"Nafis B","family":"Eghrari","sequence":"first","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Arizona State University, Tempe, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella H","family":"Yazji","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Yavari","sequence":"additional","affiliation":[{"name":"Arizona State University, Tempe, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-2417","authenticated-orcid":false,"given":"Gustaf M","family":"Van Acker","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation, MetroHealth Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong H","family":"Kim","sequence":"additional","affiliation":[{"name":"Physical Medicine and Rehabilitation, MetroHealth Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"2026100502151092000_51.10.1118.1","unstructured":"Yasaei R , Katta S , Patel P , et al . StatPearls. StatPearls Publishing; 2025. Available: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493228\/ [accessed 13 Jan 2025]"},{"key":"2026100502151092000_51.10.1118.2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.3.246"},{"key":"2026100502151092000_51.10.1118.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.05.031"},{"key":"2026100502151092000_51.10.1118.4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/papr.13165","article-title":"Gabapentin-Friend or foe?","volume":"23","author":"Russo","year":"2023","journal-title":"Pain Pract"},{"key":"2026100502151092000_51.10.1118.5","first-page":"125","article-title":"Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026100502151092000_51.10.1118.6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1128601","article-title":"The association between Gabapentin or Pregabalin use and the risk of dementia: an analysis of the National Health Insurance Research Database in Taiwan","volume":"14","author":"Huang","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026100502151092000_51.10.1118.7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.7326\/M23-0849","article-title":"Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease\u202f: A Population-Based Cohort Study","volume":"177","author":"Rahman","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026100502151092000_51.10.1118.8","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16953"},{"key":"2026100502151092000_51.10.1118.9","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","volume":"2014","author":"Moore","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100502151092000_51.10.1118.10","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100502151092000_51.10.1118.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21547"},{"key":"2026100502151092000_51.10.1118.12","doi-asserted-by":"publisher","DOI":"10.1046\/j.0003-2409.2001.02399.x"},{"key":"2026100502151092000_51.10.1118.13","article-title":"Pregabalin for neuropathic pain in adults","volume":"1","author":"Derry","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100502151092000_51.10.1118.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41394-018-0038-y","article-title":"Adverse cognitive effect of gabapentin in individuals with spinal cord injury: preliminary findings","volume":"4","author":"Shem","year":"2018","journal-title":"Spinal Cord Ser Cases"},{"key":"2026100502151092000_51.10.1118.15","doi-asserted-by":"crossref","first-page":"910719","DOI":"10.3389\/fphar.2022.910719","article-title":"The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition","volume":"13","author":"Oh","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026100502151092000_51.10.1118.16","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1007\/s10461-022-03716-3","article-title":"Functional Impairment and Cognitive Symptoms Among People with HIV Infection on Chronic Opioid Therapy for Pain: The Impact of Gabapentin and Other Sedating Medications","volume":"26","author":"Kim","year":"2022","journal-title":"AIDS Behav"},{"key":"2026100502151092000_51.10.1118.17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1212\/01.WNL.0000152877.08088.87","article-title":"Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers","volume":"64","author":"Salinsky","year":"2005","journal-title":"Neurology (ECronicon)"},{"key":"2026100502151092000_51.10.1118.18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.neurol.2023.11.006","article-title":"The effect of gabapentin and pregabalin on agitation in dementia: Case series of ten patients","volume":"180","author":"Kandemir Yilmaz","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"2026100502151092000_51.10.1118.19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.4.372"},{"key":"2026100502151092000_51.10.1118.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(99)00006-6"},{"key":"2026100502151092000_51.10.1118.21","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0595-1"},{"key":"2026100502151092000_51.10.1118.22","first-page":"55","article-title":"Psychiatric Uses of Gabapentin","volume":"19","author":"Martin","year":"2022","journal-title":"Innov Clin Neurosci"},{"key":"2026100502151092000_51.10.1118.23","doi-asserted-by":"crossref","unstructured":"Kleiman A , Koppel B , Akfirat G , et al . Gabapentin Neurotoxicity Including Posterior Reversible Leucoencephalopathy Syndrome (PRES) (P06.118). Neurology (ECronicon) 2012;78. doi:10.1212\/WNL.78.1_supplement.P06.118","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.118"},{"key":"2026100502151092000_51.10.1118.24","doi-asserted-by":"crossref","unstructured":"Hung TY , Seow VK , Chong CF , et al . Gabapentin toxicity: an important cause of altered consciousness in patients with uraemia. BMJ Case Rep 2009;2009. doi:10.1136\/bcr.11.2008.1268","DOI":"10.1136\/bcr.11.2008.1268"},{"key":"2026100502151092000_51.10.1118.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-007-9043-9"},{"key":"2026100502151092000_51.10.1118.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.11.003"},{"key":"2026100502151092000_51.10.1118.27","doi-asserted-by":"crossref","DOI":"10.1186\/1756-6606-5-18","article-title":"Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats","volume":"5","author":"Yang","year":"2012","journal-title":"Mol Brain"},{"key":"2026100502151092000_51.10.1118.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026100502151092000_51.10.1118.29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nature09612","article-title":"Regulation of synaptic connectivity by glia","volume":"468","author":"Eroglu","year":"2010","journal-title":"Nature New Biol"},{"key":"2026100502151092000_51.10.1118.30","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.142"}],"container-title":["Regional Anesthesia &amp; Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rapm-2025-106577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:15:43Z","timestamp":1791191743000},"score":1,"resource":{"primary":{"URL":"https:\/\/rapm.bmj.com\/lookup\/doi\/10.1136\/rapm-2025-106577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,5]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/rapm-2025-106577"],"URL":"https:\/\/doi.org\/10.1136\/rapm-2025-106577","relation":{},"ISSN":["1098-7339","1532-8651"],"issn-type":[{"value":"1098-7339","type":"print"},{"value":"1532-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}